Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
16.66B
Market cap16.66B
Price-Earnings ratio
20.44
Price-Earnings ratio20.44
Dividend yield
—
Dividend yield—
Average volume
2.95M
Average volume2.95M
High today
$69.47
High today$69.47
Low today
$67.00
Low today$67.00
Open price
$68.16
Open price$68.16
Volume
1.82M
Volume1.82M
52 Week high
$73.69
52 Week high$73.69
52 Week low
$39.71
52 Week low$39.71

Stock Snapshot

The current Exelixis(EXEL) stock price is $67.00, with a market capitalization of 16.66B. The stock trades at a price-to-earnings (P/E) ratio of 20.44.

During the trading session on 2026-11-19, Exelixis(EXEL) shares reached a daily high of $69.47 and a low of $67.00. At a current price of $67.00, the stock is 0.0% higher than the low and still -3.6% under the high.

Trading volume for Exelixis(EXEL) stock has reached 1.82M, versus its average volume of 2.95M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $73.69 and a low of $39.71.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $73.69 and a low of $39.71.

EXEL News

Simply Wall St 1d
Pipeline Progress Might Change The Case For Investing In Exelixis Stock

Exelixis is preparing for potential generic competition to its top seller Cabometyx around 2030, while its key pipeline drug zanzalintinib moves through late st...

Pipeline Progress Might Change The Case For Investing In Exelixis Stock
The Motley Fool 3d
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything

Exelixis (EXEL -2.75%) has crushed the broader market over the past five years. It has done so mostly thanks to Cabometyx, a cancer medicine that has been its b...

Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
TipRanks 4d
Exelixis Earnings Call Signals Growth Despite Cost Pressures

Exelixis ((EXEL)) has held its Q3 earnings call. Read on for the main highlights of the call. The Exelixis earnings call carried a strongly positive tone, supp...

Analyst ratings

56%

of 18 ratings
Buy
33.3%
Hold
55.6%
Sell
11.1%

More EXEL News

The Motley Fool 6d
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.

A decade ago, Exelixis (EXEL -1.22%) was just beginning its growth story with the launch of its star cancer treatment Cabometyx. This first indication was in ki...

Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
TipRanks 6d
Exelixis price target lowered to $57 from $60 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Exelixis (EXEL) to $57 from $60 and keeps an Equal Weight rating on the shares. The firm adjusted estimates an...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.